$87.7 Million is the total value of Puissance Capital Management LP's 7 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 200.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KDMN | Buy | KADMON HLDGS INC | $9,359,000 | -26.7% | 4,499,352 | +17.7% | 10.68% | +19.8% |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $1,045,000 | – | 284,869 | +100.0% | 1.19% | – |
| XBI | New | SPDR SERIES TRUSTs&p biotech | $716,000 | – | 9,986 | +100.0% | 0.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KADMON HLDGS INC | 10 | Q3 2020 | 16.8% |
| VIEWRAY INC | 9 | Q4 2019 | 71.6% |
| EKSO BIONICS HLDGS INC | 9 | Q4 2019 | 41.9% |
| BELLEROPHON THERAPEUTICS INC | 9 | Q4 2019 | 15.1% |
| TRACON PHARMACEUTICALS INC | 8 | Q4 2019 | 9.3% |
| CORVUS PHARMACEUTICALS INC | 8 | Q3 2020 | 1.2% |
| SCYNEXIS INC | 5 | Q2 2020 | 10.0% |
| BELLEROPHON THERAPEUTICS INC | 3 | Q3 2020 | 70.8% |
| EKSO BIONICS HLDGS INC | 3 | Q3 2020 | 27.8% |
| SCYNEXIS INC | 1 | Q3 2020 | 7.9% |
View Puissance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ViewRay, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
View Puissance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-10-16 |
| 4 | 2023-06-07 |
| 4 | 2023-05-19 |
| 4 | 2021-06-08 |
| 4 | 2021-04-26 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-14 |
| 4 | 2020-07-27 |
| 4 | 2020-05-22 |
| 13F-HR | 2020-05-15 |
View Puissance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.